<DOC>
	<DOCNO>NCT01851590</DOCNO>
	<brief_summary>The current study conduct corroborate previous observational clinical trial valid method clinically relevant experimental design . This study aim compare efficacy , safety , cost topically administer 30 % resin lacquer treatment dermatophyte toenail onychomycosis current `` best practice '' : topical 5 % amorolfine systemic terbinafine .</brief_summary>
	<brief_title>Resin vs. Amorolfine vs. Terbinafine Treatment Onychomycosis</brief_title>
	<detailed_description>The aim prospective , investigator-blinded , randomize control clinical trial explore potential difference 5 % amorolfine 30 % resin lacquer topical treatment onychomycosis . In addition , topical treatment method compare effective 'drug choice ' onychomycosis accord current guideline i.e . oral medication terbinafine . Altogether 90 patient ( aim collect 30 patient per group ) culture potassium hydroxide ( KOH ) stain verified dermatophyte onychomycosis randomly allocate 3 treatment group receive either topical treatment oral medication toenail onychomycosis classify follow : 1 . White superficial onychomycosis ( WSO ) 2 . Distal lateral subungual onychomycosis ( DLSO ) 3 . Proximal subungual onychomycosis ( PSO ) 4 . [ Total dystrophic onychomycosis ) ( TDO ) ] [ Excluded ] 5 . [ Candidal onychomycosis ] [ Excluded ] Participants randomize 3 group receive : 1 . Topical treatment : 30 % resin lacquer ( Abicin® ) apply daily 9 month . 2 . Topical treatment : 5 % amorolfine lacquer ( Loceryl® ) apply weekly 9 month . 3 . Oral medication : 250 mg terbinafine take orally daily 3 month . All patient visit outpatient department launch study , 3 9 month thereafter . Clinical examination do 4 physician . During 42-week study period , laboratory test conduct sample collect treatment , 20 week , 42 week . The test include fungal culture , KOH stain toenail sample , blood test . Cultures KOH microscopy perform independent , specialised mycology laboratory standard technique ( Medix Laboratories Ltd. , Helsinki , Finland ) . The blood test measure plasma γ-glutamyl transferase level ( also 2 week ) ; plasma creatinine level ; total number white blood cell , include neutrophil , monocyte , basophil , lymphocyte , eosinophil ; total number red blood cell , include erythrocyte haematocrit ; erythrocyte index , include mean corpuscular volume , mean corpuscular haemoglobin , mean corpuscular haemoglobin concentration , haemoglobin level ; total number thrombocyte ( initially 42 week ) . During control visit , sequential digital photograph disfigure brittle toenail acquire . In three phone call , patient ask potential treatment-related side effect , compliance treatment , patient ' perception treatment outcome , willingness continue study . In treatment arm , treatment regimen discontinue 5 week last toenail sample provide appropriate washout period final culture KOH analysis . To ensure safety ass potential contraindication treatment regimen , patient include study undergo comprehensive medical interview physical examination . To identify patient may develop intolerable adverse event due drug combination , concurrent medication cross-checked verify compatibility resin , amorolfine , terbinafine regimen begin study . All patient inform possibility develop hypersensitivity resin , amorolfine , terbinafine . If patient experience symptom correspond level hypersensitivity , drop study .</detailed_description>
	<mesh_term>Onychomycosis</mesh_term>
	<mesh_term>Amorolfine</mesh_term>
	<mesh_term>Terbinafine</mesh_term>
	<criteria>Positive dermatophyte culture begin study obtain toenail sample . Positive KOH stain begin study obtain toenail sample . Any nail disease dermatophyte culture KOH stain verify onychomycosis Onychomycosis cause yeast nondermatophyte mold Kidney failure determine plasma creatinine level ( PKrea &gt; 100 μmol/l ) Liver failure determine plasma γglutamyltransferase level ( PGT &gt; 120 U/I ) Sensitivity allergy Resin , Amorolfine Terbinafine Potential adverse crossreaction Terbinafine , Amorolfine Resin patient 's permanent medication Presence total dystrophic onychomycosis ( TDO ) Any topical oral antifungal treatment within 6 month begin study ( washout period &gt; 6 month ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Dermatophyte onychomycosis</keyword>
	<keyword>Fungal nail infection</keyword>
	<keyword>Resin Lacquer</keyword>
	<keyword>Amorolfine</keyword>
	<keyword>Terbinafine</keyword>
</DOC>